The study that started it
In 2018 our founding team was running a tissue-repair model that would not replicate. Same protocol, same cell line, same nominal compound — inconsistent results across three months. The assumption, as it always is, was that something was wrong with the model.
It was the material. Two vials of the same peptide, ordered from the same supplier eight weeks apart, tested at 96% and 71% purity. Neither matched the certificate, which was a generic PDF with no lot number on it. The 71% vial contained enough deletion sequence to shift the dose-response curve into nonsense.
That is a common story. What was uncommon was how hard it proved to find a supplier who would simply publish lot-specific test results from an independent laboratory. Most would not. Several stopped replying when asked.
What we decided to do differently
Gladiator Peptides launched in 2019 with three commitments that have not changed:
- Independent testing on every lot. Not the manufacturer's paperwork, not our own bench. An ISO 17025 accredited third-party laboratory, named on the certificate.
- Public COA library. Every released lot is published against its batch number and stays accessible indefinitely, with no account required.
- Reject rather than downgrade. Lots below specification are destroyed, not sold as a lower purity grade or blended into a passing batch.
The third commitment is the expensive one, and it is the one that matters. A supplier who sells failed material at a discount has an incentive structure fundamentally opposed to your reproducibility.
Sampling as a business model
We lead with sampler kits rather than bulk pricing, which is an unusual choice commercially. It is deliberate. If our material is what we say it is, the cheapest way to prove it is to let you buy a small amount and run your own QC. If it is not, you have lost forty dollars instead of a research quarter.
That confidence has to be earned every lot. It is not a marketing position.
What we are not
We are a research chemical supplier. We are not a pharmacy, a clinic, a supplement company or a source of medical advice, and we will not pretend otherwise to make a sale.
We do not publish dosing protocols for humans. We do not describe our products in terms of personal outcomes. We decline orders where the intended use is evidently not research, and we report attempts to obtain material for human administration. If that costs us revenue, it is revenue we do not want — the long-term viability of legitimate peptide research depends on the supply chain not being treated as a grey-market pharmacy.
Where we are
Operations and cold storage in Wilmington, Delaware. Synthesis partners are audited annually and assessed on documentation quality as much as on price.
Who we supply
University laboratories, contract research organisations, core facilities and independent research groups. We verify institutional details on first order and may request documentation before dispatch.
Who we decline
Anyone whose stated or evident intent is human or veterinary administration, resale for such purposes, or relabelling as a supplement or medicine.
Our testing methodology →
The full five-test panel, what each test answers, and how to read a certificate.
Four Standing Rules
Publish the data
Every certificate is public. A purity claim that cannot be checked is a marketing number.
Reject, never downgrade
Out-of-spec lots are destroyed. There is no discount tier for failed material.
Keep retention samples
A sealed sample of every lot is held so any dispute can be settled with evidence.
Say research, mean research
No human protocols, no outcome claims, no exceptions for a large order.
Test Us On A Small Order
Build a three-vial kit, run your own assays, and decide from the data.